ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
FREMONT, Calif., March 21, 2016 -- Zosano Pharma Corporation (NASDAQ:ZSAN) today announced that it plans to report financial results for the fourth quarter and full year 2015 on Tuesday, March 29, 2016. Zosano will host a conference call and webcast to provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) that day. The call will be hosted by Konstantinos Alataris, Ph.D., President and CEO, and Winnie W. Tso, CFO.
To participate via live webcast, please enter this event link on your web browser: http://edge.media-server.com/m/p/7md8rj2v.
To participate on the live call, please dial +1 (866) 410-5537 (domestic) or +1 (704) 908-0329 (international), and provide the conference ID 55587751, approximately 5 to 10 minutes ahead of the start of the call.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of indications. Zosano Pharma's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano Pharma's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
Zosano Contact:. Konstantinos Alataris, Ph.D. Chief Executive Officer 510-745-1200 Investor Contact: Patti Bank Westwicke Partners 415-513-1284 [email protected] Media Contact: Jamie Lacey-Moreira 410-299-3310 [email protected]
